May 12, 2016
Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in men and women combined in the United States. In 2016 about 140,000 people will be diagnosed and 50,000 will die from this disease. On average, the lifetime risk of developing colon cancer is about 5%, however, this varies widely according to individual risk factors. About 72% of cases arise in the colon and about 28% in the rectum. In recent years, introduction of a new adjuvant chemotherapy for patients with stage III colon cancer, was very successful and significantly increased disease-free survival in these patients. However, there was no improvement in disease-free survival for patients with earlier-stage (stage I and II) disease due to the lack of simple, reliable criteria for the identification of patients who are at high risk for relapse. Now, a groundbreaking study published in the New England Journal of Medicine, demonstrated that CDX2 antibodies from BioGenex (Clone CDX2-88) can be employed in a new prognostic approach and help save lives of stage II Colon Cancer patients.
The researchers in this study used a new bioinformatics approach to search for a biomarker of colon epithelial differentiation. They screened a 2329 sample pool of gene-expression arrays from primary human colon epithelial tissues and identified the transcription factor CDX2 as their leading candidate. CDX2 protein expression was analyzed in colon-cancer tissue microarrays by immunohistochemistry (IHC), using the BioGenex CDX2 antibody, clone CDX2-88. It was found that the rate of 5-year disease-free survival was only 12% in patients with CDX2-protein-negative colon cancer, compared to 88% in patients with CDX2 protein-positive tumors. These findings were independent of patient’s age, sex, and tumor stage and grade. In addition, stage II patients with CDX2-negative tumor who were treated with adjuvant chemotherapy had a much higher rate of 5-year disease-free survival (91%) as compared to patients who did not receive adjuvant chemotherapy (56% survival). These findings demonstrate that CDX2 expression can identify a subgroup of patients with high-risk stage II colon cancer who benefit from adjuvant chemotherapy.
For more details click here
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.